
Fetal Therapy for Alpha and Beta Thalassemia Major


Tippi MacKenzie, MD Professor of Surgery Co-Director, Center for Maternal-Fetal Precision Medicine UCSF






Fetal Surgery was invented 30+ years ago...





Fetal Surgery was invented 30+ years ago...







Why in utero: -fetus doesn't reject new cells

We are now moving from anatomic problems to genetic diseases like thalassemia

Harnessing Fetal Tolerance




Harnessing Fetal Tolerance



Transplanting mom's cells into fetus works in animal models




In utero transplant of maternal CD34 cells in fetal dogs -chimerism -tolerance



Engrafted animals tolerate a kidney transplant from the same donor.

Vrecenak, Blood 2014

We can do a 2-step approach



Naïve T

Treg

cell


We are now doing a clinical trial of fetal therapy in patients -Starting with alpha thalassemia

Planning to expand to beta thalassemia in 2020


Alpha Thalassemia Major

- --/-- = Hemoglobin Bart's; <u>no</u> alpha hemoglobin chain
- Fetal hydrops due to in utero hypoxia
- 5% carrier rate worldwide
- China, Southeast Asia: > 15% carrier





UCSF In Utero Stem Cell Transplantation Clinical Trial



FDA Approval - October 2016 Grant funding (CIRM)- June 2017 First patient transplanted Oct 2017

Currently recruiting patients for enrollment

First patient transplanted October 2017

- Presented with hydrops at 18 weeks
- Transplanted at 22 weeks
- Continue transfusions every 3 weeks (5 total)



Safety:

- Born at 36 3/7 weeks- no preterm labor
- Hydrops resolved

birth

What we learned:

- Hydrops resolves with careful transfusions
- Clinical protocol is feasible; appears safe



New York Times May 2018

International Prospective Registry




We are trying identify patients with alpha thalassemia majornot as rare as we think!

Goals:

- Patient and provider attitudes regarding fetal therapy vs termination
- Neurologic outcomes of fetuses who had adequate transfusions

1-800-RX-FETUS

Alpha Thal Major is NOT FATAL



Long Term Plan- Fetal Therapy

2017-2020	2020-2023	2023	
Stem Cell Transplant			
Alpha Thalassemia Major	Beta Thal Major/Sickle Cell	Others	
A statement			
	Fetal Gene Therapy		

We continue to do research to improve these therapies

Ethical considerations



- Non-directive counseling
- Cultural sensitivity
- Marginal corrections vs fetal demise
- Access to care

Patient representation critical for planning therapy

How can you get involved?

- Encourage family and friends to have screening
- Follow us on Facebook
- Connect us to families with alpha thalassemia
- Visit our booth and website
- Tell us what you think!!!



Tippi.Mackenzie@ucsf.edu

UCSF Focus Groups

for parents of children with alpha or beta thalassemia major


Tonight, 5:15 pm-6:45 pm *OR* Tomorrow 11:30 am-1:00 pm

To participate:

- Visit the UCSF table outside OR
- Complete questionnaire on CAF mobile app

Participants will receive a \$50 amazon gift card!





Thalassemia Team

Elliott Vichinsky Ashutosh Lal Sandhya Kharbanda **Billie Lianoglou** Meghan Foe Romobia Hutchinson Mark Walters Chris Dvorak **Craig Forrester** Juan Gonzalez Roberta Keller Anita Moon-Grady Marla Ferschl

Questions? <u>tippi.mackenzie@ucsf.edu</u>

1-800-RX-FETUS



THANK YOU TO OUR PATIENTS for their gracious participation in new therapies



